HC Wainwright Reiterates Buy Rating for Personalis (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 96.43% from the stock’s current price.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 price objective on shares of Personalis in a research note on Friday, December 20th.

Personalis Stock Performance

PSNL stock opened at $5.60 on Wednesday. The firm has a fifty day moving average price of $4.70 and a 200 day moving average price of $4.33. Personalis has a fifty-two week low of $1.12 and a fifty-two week high of $7.20. The firm has a market cap of $395.63 million, a PE ratio of -3.33 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same period in the previous year, the business earned ($0.51) earnings per share. On average, equities analysts predict that Personalis will post -1.41 EPS for the current year.

Institutional Trading of Personalis

Several institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its holdings in shares of Personalis by 11.4% in the third quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after buying an additional 723,637 shares during the period. Acadian Asset Management LLC grew its position in Personalis by 6.7% in the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock valued at $1,237,000 after acquiring an additional 66,128 shares during the last quarter. Geode Capital Management LLC increased its stake in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after purchasing an additional 83,068 shares during the period. State Street Corp lifted its position in shares of Personalis by 34.5% during the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after purchasing an additional 44,900 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Personalis during the third quarter valued at $897,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.